Gender differences in the proarrhythmic potential of QT-prolonging drugs.

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Female gender is associated with an increased risk of torsades de pointes (TDP) in the setting of drugs that can prolong the QT interval. These drugs are all potassium channel blocking agents and include many frequently used antiarrhythmic drugs, as well as a variety of noncardiac medications. The mechanism of this gender difference is unknown. Some women at risk are silent carriers of the long QT syndrome. The concept of "repolarization reserve" can help predict which individuals are at risk for developing drug-induced TDP. Generic formulations of QT-prolonging drugs have the potential to increase proarrhythmic risk to women. Female subjects need to be well represented in the testing of new potassium channel blocking drugs.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
JournalCurrent Women's Health Reports
Volume2
Issue number2
StatePublished - Jan 1 2002

Fingerprint

Torsades de Pointes
Pharmaceutical Preparations
Potassium Channels
Long QT Syndrome
Anti-Arrhythmia Agents

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{9a5d261cdab043afb58ca10fc15ede9d,
title = "Gender differences in the proarrhythmic potential of QT-prolonging drugs.",
abstract = "Female gender is associated with an increased risk of torsades de pointes (TDP) in the setting of drugs that can prolong the QT interval. These drugs are all potassium channel blocking agents and include many frequently used antiarrhythmic drugs, as well as a variety of noncardiac medications. The mechanism of this gender difference is unknown. Some women at risk are silent carriers of the long QT syndrome. The concept of {"}repolarization reserve{"} can help predict which individuals are at risk for developing drug-induced TDP. Generic formulations of QT-prolonging drugs have the potential to increase proarrhythmic risk to women. Female subjects need to be well represented in the testing of new potassium channel blocking drugs.",
author = "Deborah Wolbrette",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "2",
pages = "105--109",
journal = "Current Women's Health Reports",
issn = "1534-5874",
publisher = "Current Science, Inc.",
number = "2",

}

Gender differences in the proarrhythmic potential of QT-prolonging drugs. / Wolbrette, Deborah.

In: Current Women's Health Reports, Vol. 2, No. 2, 01.01.2002, p. 105-109.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Gender differences in the proarrhythmic potential of QT-prolonging drugs.

AU - Wolbrette, Deborah

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Female gender is associated with an increased risk of torsades de pointes (TDP) in the setting of drugs that can prolong the QT interval. These drugs are all potassium channel blocking agents and include many frequently used antiarrhythmic drugs, as well as a variety of noncardiac medications. The mechanism of this gender difference is unknown. Some women at risk are silent carriers of the long QT syndrome. The concept of "repolarization reserve" can help predict which individuals are at risk for developing drug-induced TDP. Generic formulations of QT-prolonging drugs have the potential to increase proarrhythmic risk to women. Female subjects need to be well represented in the testing of new potassium channel blocking drugs.

AB - Female gender is associated with an increased risk of torsades de pointes (TDP) in the setting of drugs that can prolong the QT interval. These drugs are all potassium channel blocking agents and include many frequently used antiarrhythmic drugs, as well as a variety of noncardiac medications. The mechanism of this gender difference is unknown. Some women at risk are silent carriers of the long QT syndrome. The concept of "repolarization reserve" can help predict which individuals are at risk for developing drug-induced TDP. Generic formulations of QT-prolonging drugs have the potential to increase proarrhythmic risk to women. Female subjects need to be well represented in the testing of new potassium channel blocking drugs.

UR - http://www.scopus.com/inward/record.url?scp=0036527534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036527534&partnerID=8YFLogxK

M3 - Review article

C2 - 12116598

AN - SCOPUS:0036527534

VL - 2

SP - 105

EP - 109

JO - Current Women's Health Reports

JF - Current Women's Health Reports

SN - 1534-5874

IS - 2

ER -